Evidence map›Paper›PMID 23973767›Full record

ArticleGastroenterology2013

Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver.

Abraham J Kandathil, Frederik Graw, Jeffrey Quinn, Hyon S Hwang, Michael Torbenson, Alan S Perelson, Stuart C Ray, David L Thomas, Ruy M Ribeiro, Ashwin Balagopal

Open access · greenAbstract read
In one paragraph

Article in Gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 80 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Abraham J KandathilDepartment of Medicine, Johns Hopkins University Baltimore, Maryland.
Frederik Graw
Jeffrey Quinn
Hyon S Hwang
Michael Torbenson
Alan S Perelson
Stuart C Ray
David L Thomas
Ruy M Ribeiro
Ashwin Balagopal
Johns Hopkins University · USLos Alamos National Laboratory · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Jiang Qian · 1985 to 2026
$22.1M
UNM COBRE: THEORETICAL STUDY OF SPECIFICITY OF RNA SILENCING MECHANISMP20RR018754 · NCRR · UNIVERSITY OF NEW MEXICO · PI WEARING, HELEN JANE · 2003 to 2011
$16.7M
The Progression of Hepatitis C Among IDUs with HIVR01DA016078 · NIDA · JOHNS HOPKINS UNIVERSITY · PI BALAGOPAL, ASHWIN, THOMAS, DAVID L · 2002 to 2016
$10.9M
Scientific CoreU19AI088791 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 2010 to 2020
$8.2M
Collaborative Integration of HCV Molecular Virology and Mathematical ModelingR01AI078881 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PERELSON, ALAN S, UPRICHARD, SUSAN L. · 2011 to 2025
$7.5M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
Immune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7M
Immune System Modeling/HIVR37AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 2002 to 2011
$2.4M
Viral kinetic models of HCV clearance in hemophiliacs treated with telaprevirR34HL109334 · NHLBI · UNIVERSITY OF CINCINNATI · PI SHERMAN, KENNETH E · 2012 to 2013
$713k
HIV, Kupffer Cells, and HCV-related Liver FibrosisK08AI081544 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BALAGOPAL, ASHWIN · 2009 to 2013
$644k
NCI NIH HHS P30 CA006973NCRR NIH HHS P20 RR018754NCRR NIH HHS RR 018754NEI NIH HHS EY 001765NEI NIH HHS P30 EY001765NHLBI NIH HHS HL 109334NHLBI NIH HHS R34 HL109334NIAID NIH HHS AI 028433NIAID NIH HHS AI 078881NIAID NIH HHS AI 081544NIAID NIH HHS K08 AI081544NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI078881NIAID NIH HHS R37 AI028433NIAID NIH HHS R56 AI078881NIAID NIH HHS U19 AI088791NIDA NIH HHS DA 016078NIDA NIH HHS R01 DA016078NIH HHS OD 011095NIH HHS R01 OD011095
6 · The paper itself

Abstract

BACKGROUND &

aimsHepatitis C virus (HCV) predominantly infects hepatocytes, but many hepatocytes are not infected; studies have shown that HCV antigens cluster within the liver. We investigated spatial distribution and determinants of HCV replication in human liver samples.

methodsWe analyzed liver samples from 4 patients with chronic HCV infection (genotype 1, Metavir scores 0-1) to estimate the proportion of infected hepatocytes and the amount of HCV viral RNA (vRNA) per cell. Single-cell laser capture microdissection was used to capture more than 1000 hepatocytes in grids, to preserve geometric relationships. HCV vRNA and interferon-induced transmembrane protein 3 (IFITM3) messenger RNA (the transcript of an interferon-stimulated gene) were measured in the same hepatocytes by quantitative polymerase chain reaction and assembled in maps to identify areas of high and low HCV replication.

resultsPatients' serum levels of HCV RNA ranged from 6.87 to 7.40 log10 IU/mL; the proportion of HCV-infected hepatocytes per person ranged from 21% to 45%, and the level of vRNA ranged from 1 to 50 IU/hepatocyte. Infection was not random; we identified clustering of HCV-positive hepatocytes using infected-neighbor analysis (P < .0005) and distance to the kth nearest neighbor compared with random distributions, obtained by bootstrap simulations (P < .02). Hepatocytes that expressed IFITM3 did not appear to cluster and were largely HCV negative.

conclusionsWe used single-cell laser capture and high-resolution analysis to show that in human liver HCV infects hepatocytes in nonrandom clusters, whereas expression of antiviral molecules is scattered among hepatocytes. These findings show that quantitative single-cell RNA measurements can be used to estimate the abundance of HCV vRNA per infected human hepatocyte and are consistent with cell-cell propagation of infection in the absence of clustered IFITM3.

Indexed as

AdultBiopsyCross-Sectional StudiesFemaleHepacivirusHepatitis CHepatocytesHumansImmunity, InnateLaser Capture MicrodissectionLiverMaleMembrane ProteinsMiddle AgedRetrospective StudiesRNA-Binding ProteinsIFITM3 protein, humanMembrane ProteinsRNA-Binding ProteinsRNA, ViralAIDS Linked to Intravenous ExperienceALIVEcDNAcomplementary DNAHCVhepatitis C virusHIVhuman immunodeficiency virusIFITM3interferon-induced transmembrane protein 3interferon-stimulated geneIntrahepatic InfectionISGlaser-capture microdissectionLCMmessenger RNAmRNAPCRpolymerase chain reactionqPCRquantitative polymerase chain reactionscLCMsingle-cell laser-capture microdissectionviral RNAVirologyvRNA

Identifiers

PMID23973767
PMCPMC4005338
OpenAlexW2068700454

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.